PFS
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C O'Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Mueller, Shan Yang, Giovanna Granata, Qi Shen, Libero Santarpia, Erika Hamilton, HER2CLIMB-05 Investigators
J Clin Oncol 44(17) 1597-1607
PURPOSE: The HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance therapy in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). METHODS: Patients with centrally confirmed HER2+ MBC without evidence of progression post induction therapy and no or asymptomatic brain metastases (BM) were enrolled. Patients were randomly assigned 1:1 to tucatinib (300 mg) or placebo twice a day combined with trastuzumab/pertuzumab. The primary end point is investigator-assessed progression-free survival (PFS); secondary end points include overall survival (OS), PFS per blinded independent central review, CNS-PFS, and safety. RESULTS: Between March 2022 and July 2024, 654 patients were randomly assigned to tucatinib (n = 326) and placebo (n = 328) arms. All patients were female (median age, 54 years), 69.3% had de novo MBC, 52.6% were hormone receptor-positive, and 12.4% had presence/history of baseline BM. In this primary analysis, PFS was statistically significantly improved with addition of tucatinib versus placebo (hazard ratio, 0.641 [95% CI, 0.514 to 0.799]; P < .0001; median PFS: 24.9 v 16.3 months); a PFS benefit was seen regardless of the presence/absence of BM or hormone receptor status. OS data remain immature. The most common treatment-emergent adverse events (TEAEs) in the tucatinib arm were diarrhea (72.7%), nausea (33.1%), and elevated liver enzymes (ALT: 28.2%; AST: 25.8%), of which 6.1%, 0.9%, 13.5%, and 7.1%, respectively, were grade ≥3. In the tucatinib arm, 13.5% discontinued tucatinib because of TEAEs. CONCLUSION: Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L maintenance therapy in patients with HER2+ MBC.
5 个 Figure · 7 个 KM 面板
FIG 2. Kaplan–Meier estimate of (A) investigator-assessed PFS in the ITT analysis population and (B) forest plot of subgroup analyses. The random assignment stratification factors used in the Cox proportional-hazards model for computing HRs are diagnosis (de novo or recurrent), hormone receptor status (positive or negative), and presence or history of brain metastases (yes or no). If the subgroup is defined by a random assignment stratification factor, the Cox model is stratified for the random assignment stratification factors other than the one that defines the subgroup. Two-sided P value based on the stratified log-rank test. CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor; HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PD, progressive disease; PERT, pertuzumab; PFS, progression-free survival; PR, partial response; SD, stable disease; TRAS, trastuzumab; TUC, tucatinib.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. Kaplan–Meier estimate of OS in the ITT analysis population. HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; PBO, placebo; PERT, pertuzumab; TRAS, trastuzumab; TUC, tucatinib.
FIG 3. · Panel OS_Probability
Panel OS_Probability 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A1. Kaplan-Meier estimate of PFS in the ITT analysis population assessed by blinded independent central review. HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.
FIG A1. · Panel Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population
Panel Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. Kaplan-Meier estimates of investigator-assessed PFS in patients with (A) hormone receptor–negative and (B) hormone receptor–positive HER2+ MBC. HER2+, human epidermal growth factor receptor 2–positive; HR, hazard ratio; MBC, metastatic breast cancer; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.
FIG A2. · Panel A
Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. · Panel B
Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A3. Kaplan-Meier estimates of (A) investigator-assessed CNS-PFS in the ITT analysis population and (B) patients with BM at baseline. BM, brain metastases; HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.
FIG A3. · Panel A
Panel A 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A3. · Panel B
Panel B 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。